BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia.
Benyamine A, Le Roy A, Mamessier E, Gertner-Dardenne J, Castanier C, Orlanducci F, Pouyet L, Goubard A, Collette Y, Vey N, Scotet E, Castellano R, Olive D.
Benyamine A, et al. Among authors: collette y.
Oncoimmunology. 2016 Apr 25;5(10):e1146843. doi: 10.1080/2162402X.2016.1146843. eCollection 2016.
Oncoimmunology. 2016.
PMID: 27853633
Free PMC article.